The Prague Post - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.183608
AFN 75.185325
ALL 93.475856
AMD 416.380642
AOA 1045.760713
ARS 1688.928865
AUD 1.62924
AWG 2.051935
AZN 1.942914
BAM 1.953841
BBD 2.294689
BDT 140.529083
BHD 0.429967
BIF 3396.17954
BMD 1.139173
BND 1.470525
BOB 12.56035
BRL 5.780619
BSD 1.139253
BTN 109.963733
BWP 15.492397
BYN 3.287703
BYR 22327.784586
BZD 2.291292
CAD 1.603431
CDF 2574.530657
CHF 0.929561
CLF 0.027128
CLP 1067.655673
CNY 7.715592
CNH 7.715622
COP 3666.199446
CRC 516.879425
CUC 1.139173
CUP 30.188076
CVE 110.154541
CZK 24.186238
DJF 202.878343
DKK 7.475678
DOP 66.214765
DZD 151.647825
EGP 58.439328
ERN 17.08759
ETB 183.887398
FJD 2.556534
FKP 0.85166
GBP 0.853236
GEL 2.996121
GGP 0.85166
GHS 13.232673
GIP 0.85166
GMD 83.734331
GNF 9995.976432
GTQ 8.691247
GYD 238.319976
HKD 8.93268
HNL 30.516935
HRK 7.533806
HTG 148.963241
HUF 364.503375
IDR 20470.19265
ILS 3.500245
IMP 0.85166
INR 110.110894
IQD 1492.529554
IRR 1566647.232079
ISK 143.410726
JEP 0.85166
JMD 180.479023
JOD 0.807646
JPY 186.237703
KES 147.534026
KGS 99.620428
KHR 4597.470555
KMF 492.122132
KRW 1677.738898
KWD 0.352905
KYD 0.949448
KZT 532.663528
LAK 25797.018549
LBP 102022.348256
LKR 382.916027
LRD 206.206888
LSL 18.701665
LTL 3.363681
LVL 0.689074
LYD 7.306673
MAD 10.678592
MDL 20.062794
MGA 4891.073958
MKD 61.508322
MMK 2391.388129
MNT 4090.960131
MOP 9.202032
MRU 45.526348
MUR 53.757852
MVR 17.611752
MWK 1975.536353
MXN 19.895263
MYR 4.657735
MZN 72.804425
NAD 18.702075
NGN 1560.028855
NIO 41.927956
NOK 10.949671
NPR 175.941573
NZD 1.969303
OMR 0.438011
PAB 1.139253
PEN 3.868021
PGK 5.100885
PHP 70.397477
PKR 316.524602
PLN 4.327563
PYG 6897.083879
QAR 4.153235
RON 5.234611
RSD 117.435047
RUB 89.310702
RWF 1676.518854
SAR 4.271472
SBD 9.202102
SCR 15.252961
SDG 684.078591
SEK 11.09426
SGD 1.471156
SLE 27.625007
SOS 651.147056
SRD 42.987252
STD 23578.574557
STN 24.47535
SVC 9.969003
SZL 18.700166
THB 38.533644
TJS 10.526721
TMT 3.998496
TND 3.372418
TRY 53.806313
TTD 7.732213
TWD 36.819883
TZS 3001.717747
UAH 51.063595
UGX 4277.691725
USD 1.139173
UYU 45.75412
UZS 13788.173768
VES 839.523846
VND 29979.037911
VUV 135.588974
WST 3.124487
XAF 655.299891
XAG 0.019494
XAU 0.000279
XCD 3.078671
XCG 2.053332
XDR 0.81309
XOF 655.299891
XPF 119.331742
YER 271.81464
ZAR 18.731872
ZMK 10253.922663
ZMW 21.105743
ZWL 366.813139
  • BCE

    -0.1000

    21.36

    -0.47%

  • BCC

    -0.6200

    77.08

    -0.8%

  • CMSC

    -0.0850

    21.91

    -0.39%

  • RIO

    -0.1500

    92.15

    -0.16%

  • RBGPF

    0.4200

    67.77

    +0.62%

  • CMSD

    -0.0500

    22.1

    -0.23%

  • NGG

    -1.8950

    81.96

    -2.31%

  • BTI

    -1.4500

    60.59

    -2.39%

  • GSK

    -0.4550

    50.31

    -0.9%

  • AZN

    -2.3100

    167.46

    -1.38%

  • VOD

    0.0000

    15.51

    0%

  • RELX

    0.2400

    32.955

    +0.73%

  • BP

    0.9450

    44.27

    +2.13%

  • RYCEF

    -0.0800

    18.17

    -0.44%

  • JRI

    0.0330

    12.955

    +0.25%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

D.Kovar--TPP